CLOs on the Move

MSI

www.methylationsciences.com

 
MSI Methylation Sciences Inc. (“MSI”) is a clinical-stage pharmaceutical company focused on developing new products based on molecules which have clinical proof of concept but which have yet to be exploited in the major pharmaceutical markets. MSI`s focus is in the CNS space where clinical proof of concept is key to reducing the drug development risk. Our lead product candidate, Strada™, is based upon Ademetionine, a naturally occurring molecule produced throughout the body, where it plays a vital role in the one-carbon cycle. Our disease indication is Major Depressive Disorder (MDD).
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Similar Companies

High Rocks Inc

High Rocks Inc is a Cedar Mountain, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Westphalia Retirement Ctr

Westphalia Retirement Ctr is a Westphalia, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

OPTIVIO

OPTIVIO is an enterprise level stress management platform, offering powerful analysis and training to identify and overcome your leading sources of stress.

Prairie Senior Cottages

Prairie Senior Cottages is a Willmar, MN-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Enterin Inc.

Enterin is pioneering the medical community`s understanding of the link between infections, dysfunction of the enteric nervous system (ENS) of the gut, and the early onset and chronic progression of neurodegenerative disease. We are leveraging years of research to become the first company in the world to develop a novel drug that repairs the dysfunctional gut-brain axis in patients with neurodegenerative disease. Our lead compound, ENT-01 (also known as kenterin), displaces membrane-bound alpha- synuclein (αS) aggregates from nerve cells in the ENS and improves neural signaling between the gut and the brain in preclinical models of Parkinson`s disease. In the gut, this results in improved motility. We are now progressing this drug through clinical trials in an attempt to reverse the constipation of Parkinson`s disease. Our long-term mission is to become the world leader in developing pharmaceutical therapies that repair the gut-brain axis.